Obesity drugs cut blood pressure

Researchers at the European Congress on Obesity in Istanbul reported that newer obesity medicines were linked to meaningful reductions in blood pressure across phase 3 trial programs presented May 12-15, 2026. (eurekalert.org) The headline number from the meta-analysis was a 0.34 mmHg drop in systolic blood pressure for every 1% reduction in body weight, based on 32 studies involving 43,618 adults, according to a European Association for the Study of Obesity release naming Dr. Marcel Muskiet of Leiden University Medical Center and Professor David Cherney of the University of Toronto among the researchers. (eurekalert.org) That matters because the analysis was not a single-company drug readout. The researchers pooled phase 3 clinical trial programs covering GLP-1 receptor agonists and newer multi-hormone medicines, including dual GLP-1/GIP drugs, to examine how weight loss tracked with blood-pressure change. (eurekalert.org) The framing from the investigators was specific: obesity treatment is already part of blood-pressure management, but the exact relationship between weight loss and blood-pressure lowering with these newer medicines has been less clear. They said the drugs may have both weight-dependent and weight-independent effects on blood pressure, which is one reason they ran the meta-analysis. (eurekalert.org) The data presented at ECO 2026 add to a broader body of evidence that the newest obesity medicines can improve more than body weight alone. A 2025 Nature Medicine systematic review and meta-analysis found tirzepatide and semaglutide were among the most effective obesity medicines for reducing weight and obesity-related complications, while an American College of Cardiology summary of prior semaglutide data said blood-pressure reductions had been seen even across patients with different starting blood-pressure levels. (pmc.ncbi.nlm.nih.gov) What the Istanbul presentation does not do is settle whether blood-pressure lowering is identical across individual drugs, doses or patient groups. The conference materials summarized in the release describe a pooled relationship across trial programs rather than a head-to-head comparison of every medicine. (eurekalert.org) It also does not amount to a new treatment guideline by itself. But the congress took place as the European Association for the Study of Obesity is already updating its medication-management framework, which says obesity medicines differ in efficacy and in their effects on specific complications and should be matched to individual patient needs. (easo.org) For clinicians, the practical takeaway is narrower than the hype around weight-loss drugs. The new finding supports counting blood pressure among the measurable cardiometabolic changes to watch when patients lose weight on GLP-1-based and other next-generation obesity medicines, alongside weight itself. That is an inference from the conference analysis and the EASO framework, not a new formal recommendation in the conference release. (eurekalert.org) The next public checkpoint is likely to be fuller publication of the ECO 2026 findings or incorporation into future society guidance. ECO 2026 ran from May 12 to May 15 in Istanbul, and EASO has said an updated 2026 obesity medication algorithm is being developed from peer-reviewed evidence. (eco2026.org)